Jump Financial LLC trimmed its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 42.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,100 shares of the company's stock after selling 31,687 shares during the period. Jump Financial LLC owned approximately 0.07% of Evolus worth $476,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the stock. Geode Capital Management LLC grew its position in shares of Evolus by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company's stock valued at $13,412,000 after buying an additional 3,969 shares during the last quarter. Schroder Investment Management Group grew its position in Evolus by 2.5% during the 4th quarter. Schroder Investment Management Group now owns 1,040,440 shares of the company's stock worth $11,330,000 after purchasing an additional 25,480 shares during the last quarter. Lord Abbett & CO. LLC grew its position in Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock worth $16,126,000 after purchasing an additional 188,685 shares during the last quarter. Rice Hall James & Associates LLC grew its position in Evolus by 4.8% during the 4th quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock worth $10,469,000 after purchasing an additional 43,381 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Evolus by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 421,481 shares of the company's stock worth $4,653,000 after purchasing an additional 2,905 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
EOLS has been the topic of several analyst reports. BTIG Research started coverage on shares of Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday, April 9th. Barclays raised their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus has an average rating of "Buy" and a consensus target price of $23.75.
Check Out Our Latest Research Report on Evolus
Evolus Price Performance
EOLS traded down $0.17 during midday trading on Wednesday, reaching $11.40. 573,860 shares of the company's stock were exchanged, compared to its average volume of 667,307. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market capitalization of $724.89 million, a PE ratio of -12.53 and a beta of 0.97. The business's 50-day moving average price is $12.07 and its 200 day moving average price is $12.84. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82.
Insider Activity
In other news, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the transaction, the insider now owns 362,467 shares of the company's stock, valued at $4,806,312.42. The trade was a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the transaction, the director now directly owns 32,183 shares of the company's stock, valued at approximately $418,057.17. This represents a 28.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,575 shares of company stock valued at $794,369 over the last 90 days. Insiders own 6.10% of the company's stock.
Evolus Company Profile
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
